Cargando…

Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis

BACKGROUND: Subcutaneous peginterferon beta-1a every 2 weeks significantly affects clinical outcomes in patients with relapsing–remitting multiple sclerosis (RRMS). OBJECTIVES: To explore relationships between relapses and worsening of disability in patients with RRMS, and assess the treatment effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scott, Thomas F, Kieseier, Bernd C, Newsome, Scott D, Arnold, Douglas L, You, Xiaojun, Hung, Serena, Sperling, Bjoern
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433498/ https://www.ncbi.nlm.nih.gov/pubmed/28607743 http://dx.doi.org/10.1177/2055217316676644

Ejemplares similares

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis
por: Newsome, Scott D., et al.
Publicado: (2016)

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis
por: Arnold, Douglas L, et al.
Publicado: (2014)

Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial
por: Arnold, Douglas L., et al.
Publicado: (2017)

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE
por: Kieseier, Bernd C, et al.
Publicado: (2015)

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
por: Newsome, Scott D., et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
por: Hu, Xiao, et al.
Publicado: (2015)

Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis
por: Hu, Xiao, et al.
Publicado: (2017)

A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Tolley, Keith, et al.
Publicado: (2015)

Pregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing–Remitting Multiple Sclerosis
por: Kieseier, Bernd C., et al.
Publicado: (2014)

Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study
por: Arnold, Douglas L., et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
por: Hu, Xiao, et al.
Publicado: (2015)

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis
por: Arnold, Douglas L., et al.
Publicado: (2018)

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
por: Hendin, Barry, et al.
Publicado: (2018)

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
por: Kolb-Mäurer, Annette, et al.
Publicado: (2019)

Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study
por: Menge, Til, et al.
Publicado: (2021)

Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients
por: Hang, Yaming, et al.
Publicado: (2016)

New immunopathologic insights into multiple sclerosis
por: Hemmer, Bernhard, et al.
Publicado: (2003)

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
por: Hu, Xiao, et al.
Publicado: (2016)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis
por: Yu, Huixin, et al.
Publicado: (2022)

Multiple Sclerosis Susceptibility Genes: Associations with Relapse Severity and Recovery
por: Mowry, Ellen M., et al.
Publicado: (2013)

Relapse recovery: The forgotten variable in multiple sclerosis clinical trials
por: Kantarci, Orhun H., et al.
Publicado: (2019)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
por: Madsen, Claus
Publicado: (2017)

Early Aggressive Treatment Approaches for Multiple Sclerosis
por: Simpson, Alexandra, et al.
Publicado: (2021)

Era of COVID-19 in Multiple Sclerosis Care
por: Krett, Jonathan D., et al.
Publicado: (2023)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Paolicelli, Damiano, et al.
Publicado: (2009)

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
por: Jankovic, Slobodan M
Publicado: (2010)

Approved Beta Interferons in Relapsing-Remitting Multiple Sclerosis: Is There an Odd One Out?
por: Clapin, Alexis
Publicado: (2012)

The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil
por: Lemos, Livia Lovato Pires de, et al.
Publicado: (2017)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

How patients with multiple sclerosis acquire disability
por: Lublin, Fred D, et al.
Publicado: (2022)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial
por: Bar-Or, Amit, et al.
Publicado: (2022)

Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity
por: Freund, Patrick, et al.
Publicado: (2010)

Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
por: Sotiropoulos, Marinos G, et al.
Publicado: (2021)

Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era
por: Coyle, Patricia K., et al.
Publicado: (2021)

Multiple sclerosis and COVID-19: A great opportunity for databases promoting research and collaboration
por: Racke, Michael K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mf3vu2v1v10c7moochglbosb0r